Welcome to our dedicated page for RoboStrategy news (Ticker: BOT), a resource for investors and traders seeking the latest updates and insights on RoboStrategy stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RoboStrategy's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RoboStrategy's position in the market.
RoboStrategy (Nasdaq: BOT), a registered closed-end fund focused on private robotics and physical AI companies, reported updated net asset values as of July 31, 2026. Net assets applicable to common shares were $274,578,031.45, with a NAV per share of $11.32.
According to RoboStrategy, total net assets rose 10.33% from $248,861,199.73 on June 30, 2026, while NAV per share increased 7.71% from $10.51, reflecting month-over-month portfolio value appreciation for shareholders.
RoboStrategy (Nasdaq: BOT), a registered closed-end fund focused on private robotics and physical AI companies, completed a series of private share issuances between July 7 and July 14, 2026. The Fund issued 450,684 common shares at a weighted average price of approximately $35.50, raising gross proceeds of about $15.999 million with no placement fees or commissions.
Participants included institutional investors and CEO Andrew Kang, who invested roughly $10.0 million for 272,405 shares at $36.71, the July 14 Nasdaq closing price. His related-party investment was approved by independent directors. The unregistered shares were issued under Section 4(a)(2) and Regulation D, with RoboStrategy planning a resale registration statement and indicating it may continue accretive private issuances as it deploys capital into its target market.
RoboStrategy (Nasdaq: BOT) reported updated net asset value and new private placements. As of June 30, 2026, net assets were $248.9 million with 23,686,066 shares outstanding and NAV per share of $10.51.
This reflects a 29.9% increase in net assets and a 17.8% rise in NAV per share since June 22, 2026. The fund also raised about $7.6 million via 219,596 privately placed shares at a weighted average price of $34.61 to support follow-on investments in private robotics and physical AI companies.
RoboStrategy (Nasdaq: BOT), a closed-end fund focused on private robotics and physical AI companies, completed a series of private share issuances to institutional investors from June 26–29, 2026.
The Fund sold 1,346,668 common shares at a weighted average price of $25.17, raising gross proceeds of about $33.9 million before expenses, and plans to use net proceeds for follow-on investments and other capital deployments in its portfolio.
RoboStrategy (Nasdaq: BOT), a closed-end fund focused on private robotics and physical AI companies, completed private share issuances to institutional investors between June 19 and June 25, 2026.
The Fund issued 1,231,130 shares at a weighted average price of $29.65, raising approximately $36.5 million in gross proceeds with no placement fees or commissions. The unregistered shares were issued under Section 4(a)(2) and Regulation D. RoboStrategy plans to file a resale registration statement and may continue accretive private share issuances to fund investments in its target market.
RoboStrategy (Nasdaq: BOT), a closed-end fund focused on private robotics and physical AI companies, reported updated net asset value as of June 22, 2026.
Net assets were $191,590,951.94 and NAV per share was $8.92, up 30.5% and 23.2% respectively from May 31, 2026.
RoboStrategy (Nasdaq: BOT), a closed-end fund focused on private robotics and physical AI companies, completed private share issuances to institutional investors between June 11 and June 16, 2026.
The Fund issued 797,434 shares at a weighted average price of $36.28, raising approximately $28.9 million in gross proceeds.
GiantLeap Capital announced a strategic investment in Standard Bots/b) as part of a financing that values the company at $1 billion. Standard Bots, described as America’s largest manufacturer of AI-native industrial robots, uses demonstration-based training to expand automation across multiple sectors.
The company has deployed systems at hundreds of U.S. manufacturers, including Lockheed Martin, NASA, and the U.S. Army, and is expected to account for about 10% of new U.S. industrial robot deployments next year. Funds are expected to expand U.S. manufacturing capacity, AI development, and nationwide robot deployment.
Standard Bots (BOT) raised a $200 million Series C at a $1 billion valuation, led by RoboStrategy and existing investors including General Catalyst. The company is expanding its Glen Cove, New York facility to 70,000 square feet to scale vertically integrated, American-made AI-native industrial robots and targets 10% of new U.S. industrial robot deployments by next year.
Standard Bots, which describes itself as America's largest maker of AI-native industrial robots, raised $200 million Series C at a $1 billion valuation led by RoboStrategy (Nasdaq: BOT) and existing investors including General Catalyst.
The company is expanding its Glen Cove, New York facility to 70,000 square feet, vertically integrating U.S. manufacturing and aiming to deliver 10% of new U.S. industrial robot deployments by next year. Standard Bots builds no-code AI robot arms and industrial humanoids for major manufacturers and SMBs, and advises U.S. policymakers on a National Robotics Strategy.